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Abstract 
 
While hot melt extrusion is now established within the pharmaceutical industry, the 
prediction of miscibility, processability and structural stability remains a pertinent 
issue, including the issue of whether molecular interaction is necessary for suitable 
performance. Here we integrate the use of theoretical and experimental drug-polymer 
interaction assessment with determination of processability and structure of dispersions 
in two polyvinylpyrrolidone-based polymers (PVP and PVP vinyl acetate, PVPVA). 
Caffeine and paracetamol were chosen as model drugs on the basis of their differing 
hydrogen bonding potential with PVP. Solubility parameter and interaction parameter 
calculations predicted a greater miscibility for paracetamol, while ATR-FTIR 
confirmed the hydrogen bonding propensity of the paracetamol with both polymers, 
with little interaction detected for caffeine. PVP was found to exhibit greater interaction 
and miscibility with paracetamol than did PVPVA.  It was noted that lower processing 
temperatures (circa 40oC below the Tg of the polymer alone and Tm of the crystalline 
drug) and higher drug loadings with associated molecular dispersion up to 50% w/w 
were possible for the paracetamol dispersions, although molecular dispersion with the 
non-interactive caffeine was noted at loadings up to 20% w./w.  A lower processing 
temperature was also noted for caffeine-loaded systems despite the absence of 
detectable interactions. The study has therefore indicated that theoretical and 
experimental detection of miscibility and drug-polymer interactions may lead to 
insights into product processing and extrudate structure, with direct molecular 
interaction representing a helpful but not essential aspect of drug-polymer combination 
prediction.      
 
Keywords: HME; solid dispersion; hot melt extrusion; solubility parameter; melting 
point depression; polyvinylpyrrolidone
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1. Introduction 
 
 Solid dispersion formulations, whereby drugs are dispersed in water-miscible 
polymers using techniques such as hot melt extrusion, have attracted considerable 
attention due to the potential for enhancing bioavailability of poorly soluble drugs 
(Huang and Dai, 2014). In theory, an ideal solid dispersion would comprise a 
homogeneous mixture of the active pharmaceutical ingredient (API) and carrier as a 
stable one-phase system whereby the drug is present as a molecular dispersion, thereby 
negating the necessity to break down the lattice structure prior to dissolution.  Almost 
invariably, the polymer is wholly or largely amorphous in nature and hence the products 
obtained are glassy materials whereby kinetic and thermodynamic stability must be 
carefully considered.  Alternatively, a two phase system may be formed either on 
manufacture or storage, effectively representing a solid suspension.  While the precise 
relationship between phase separation and product performance has not been fully 
established, the general belief is that molecular miscibility is desirable and hence most 
studies have been conducted with this aim in mind.    
 In this study we focus on the role of direct molecular interactions on the 
processing and structural properties of HME systems, particularly with a view to 
investigating the role of such interactions in determining miscibility, processability and 
subsequent solid structure.  As outlined above, within the field miscibility is generally 
perceived as being a highly desirable characteristic of drug-polymer systems (Thakral 
and Thakral, 2013), while direct molecular interaction is considered to be a significant 
contributing factor to miscibility, ergo such interactions are desirable or indeed 
essential.  It is this assumption that we wish to explore here by using two systems of 
broadly similar polarity and molecular weight but with clear differences in the extent 
of molecular interaction with the polymers under study. 
 A number of theoretical approaches have been explored in order to predict 
miscibility and interaction, including the well-known Flory-Huggins approach, the 
Hansen solubility parameter approach and, more recently, the perturbed-chain statically 
associating fluid theory (PC-SAFT) (Prudic et al., 2014).  Amongst these methods, the 
Flory-Huggins theory has been widely used for the miscibility prediction of solid 
phases (Huang and Dai, 2014; Marsac et al., 2006; Zhao et al., 2011); the approach 
involves calculation of an interaction parameter (χ) between the components and 
incorporates consideration of the molecular weight, composition and size of the 
5 
 
molecule, hence the inherent physical dissimilarity of the API and polymer are to some 
extent accounted for. The interaction parameter may be calculated via measurement of 
the melting point depression (described in more detail below) and may lead to a 
comprehensive assessment of the thermodynamic drivers and extent of miscibility.  In 
contrast, the Hansen solubility parameter approach predicts miscibility on the basis of 
the intrinsic chemical similarity of the components. In this method, the solubility 
parameter δ may be obtained empirically as sum of the different contribution forces i.e. 
dispersive, polar and hydrogen bond interaction, with components showing similar 
solubility parameters being predicted to have high mutual solubility.  The solubility 
parameter approach is generally considered to be more suitable for non-polar or slightly 
polar systems and the Flory-Huggins approach to more polar compounds (Li et al, 
2013).  As a solid dispersion is typically composed of a polar polymer and a non-polar 
drug, both approaches may be potentially applicable.   
 It is noteworthy that the Flory-Huggins approach indicates that adhesive 
interaction between the drug and polymer is a pre-requisite for the required enthalpic 
component of the free energy of mixing (Thakral and Thakral, 2013), hence such 
interactions are predicted to be essential for forming a stable molecular dispersion.  
However, both approaches are arguably indistinct as the Flory-Huggins interaction 
parameter may be calculated from the difference in the drug and polymer solubility 
parameters, with a smaller difference leading to a small positive value of χ which in 
turn favors miscibility.  Similarly, any system in which miscibility is noted is by 
definition interactive to some extent.  Nevertheless, there is still some uncertainty as to 
how a measurable and distinct molecular interaction, as opposed to a similarity in 
molecular polarity, may contribute to miscibility or indeed whether such interactions 
are a pre-requisite to the favorable performance characteristics association with 
processability, structure and dissolution.      
 In terms of solid dispersion preparation, hot melt extrusion (HME) has become 
recognized as a robust and scalable method of manufacture. The method involves 
application of mechanical mixing to a heated sample followed by extrusion and/or 
shaping in a single continuous process (Netchacovitch et al., 2015). The practical and 
economic feasibility of the approach, together with the favorable dissolution 
performance of the incorporated API, has attracted great interest within the 
pharmaceutical industry (Kanaujia et al., 2011; Li et al., 2014; Tian et al., 2013). In 
order to successfully extrude polymer-based amorphous dispersions, the extrusion 
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temperature is typically set 30 to 60 oC higher than the Tg (glass transition temperature) 
or Tm (melting temperature) of the polymer to ensure good flowability of the mixture 
during the extrusion process (Chokshi et al., 2005; Li et al., 2014; McGinity et al., 
2006). However, given that the choice of a high Tg polymer is often preferred due to 
the physical stabilisation of the amorphous solid dispersions (Hancock and Zografi, 
1997; Sathigari et al., 2012; Shah et al., 2013), the Tg of many pharmaceutically 
acceptable polymers may be too high for the extrusion process for reasons of cost or 
heat-induced degradation; hence, a more moderate working temperature is required and 
there is therefore a balance between stabilization of the system and feasibility of 
manufacture.  The issue of minimizing processing temperature via molecular 
interactions, which is itself related to miscibility, so as to reduce the risk of degradation 
has been highlighted by Li et al. (2014) who discussed the possibility of extrusion at 
temperatures below the melting point of the drug via judicious use of interacting 
systems.  Here we examine the role of such interactions in reducing the extrusion 
temperature below the Tg of the polymer itself with a concomitant view to examining 
the capacity for forming molecular dispersions using interactive and (effectively) non-
interactive systems.        
One candidate for manufacture using HME is the hydrophilic synthetic polymer 
polyvinylpyrrolidone (PVP), which has a Tg value commensurate with drug-loaded 
HME production but is also reported to directly interact with some drugs so as to 
enhance stabilization of the molecular dispersion (Chauhan et al., 2013; Huang and Dai, 
2014; Li et al., 2013; Wegiel et al., 2015). PVP is also reported to inhibit and retard the 
recrystallization of the API via formation of a network around the drug molecules or 
growing crystal surface (Tantishaiyakul et al., 1999); both effects limit the molecular 
mobility of the API (Ozaki et al., 2013). However, use of this polymer has been limited 
by concerns regarding thermal degradation and hygroscopicity.  However, appropriate 
exploration of processing parameters and composition, based on appreciation of the 
molecular interactions between the drug and polymer, may lead to effective 
manufacture at moderate temperatures and hence prevention of deselection of a useful 
and effective polymer. We examine both PVP and the vinyl acetate derivative, PVPVA, 
both of which are credible materials for HME processing.    
The approach of the current study is threefold, with all aspects being interrelated 
in terms of developing fundamental understanding of drug-polymer interactions as a 
means of predicting dispersion behavior. Firstly, we study the miscibility of APIs with 
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PVP using the Hansen solubility parameter approach and the measurement of 
interaction parameters obtained via melting point depression approaches (Marsac et al., 
2009). We compare theoretical to experimental data to ascertain the effectiveness of 
these theoretical approaches as an early predictor of miscibility in the final product.  
Secondly, we examine the extent to which the miscibility and interaction may itself be 
used to reduce the processing temperature of the HME via plasticization effects, thereby 
reducing the risk of thermal degradation. Finally we explore the role of direct 
interaction between the drug and polymer via the use of two API systems (caffeine and 
paracetamol) which, while nominally similar in terms of molecular weight, have very 
different levels of molecular interaction with PVP (Illangakoon et al., 2014). These 
APIs therefore provide a useful model for investigating the extent to which such 
interactions may play a role in miscibility, processing and performance.    
 
2. Materials and methods 
 
2.1 Materials  
Povidone® K29-32 (PVP K29-32) and Plasdone® S630 (PVPVA 6:4) were 
generous gifts from ISP (Switzerland). Paracetamol (PCM) was obtained from Rhodia 
Organique, whereas caffeine (CAF) was purchased from Acros Organics (New Jersey, 
USA).  
 
2.2 Theoretical prediction of drug-polymer miscibility  
 Prior to the preparation of solid dispersions, the miscibility of the drug-polymer 
systems was investigated using a range of predictive approaches. 
 
2.2.1 Solubility parameter calculation 
 The solubility parameter approach is a widely used method in estimating the 
miscibility and compatibility of a mixture system. The original concept of this approach 
is described by Hildebrand (Van Krevelen and Te Nijenhuis, 2009) who stated that 
solubility of a given solute in a solvent is determined by the cohesive energy density 
i.e. the cohesive energy per unit volume of the substance. This concept is developed to 
specify the solubility parameter that is defined as the square root of the cohesive density 
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energy. Solubility is favoured when structures of solute and solvent possess similar 
solubility parameters (Van Krevelen and Te Nijenhuis, 2009).  The cohesive energy is 
closely related to the molar heat of evaporation ΔHvap, as presented in Equation (1) 
 
Ecoh = ΔHvap – pΔV ≈ ΔHvap  - RT                                    (1) 
 
where Ecoh  is cohesive energy, p is pressure, ΔV is the volume change, R is the universal 
gas constant and T is temperature. Since it is not possible to obtain the vaporization 
energy of a polymer directly, group contribution methods were developed to estimate 
the solubility parameter of polymeric systems.  More specifically, the Hoftyzer/ Van 
Krevalen and the Hoy methods (Van Krevelen and Te Nijenhuis, 2009) consider the 
cohesive energy to be dependent on different forces in the molecule which include 
dispersive (Fdi), hydrogen bond (Ehi) as well as polar forces (Fpi). The values of these 
forces are given in a reference table in Van Krevelen and Te Nijenhuis (2009).  With 
knowledge of these forces, the solubility parameter of a molecule can be estimated. 
Miscibility of the components may be estimated from the difference in the solubility 
parameter, as will be discussed in a later section. 
2.2.2 Flory-Huggins approach 
 The Flory-Huggins theory has been used for calculating free energy of mixing and 
estimating miscibility of drug-polymer components (Marsac et al., 2006; Tian et al., 
2013; Zhao et al., 2011). In considering the mixing of a large molecular weight polymer 
and a low molecular weight API, the Flory Huggins approach suggests a hypothetical 
“lattice” in space. It assumes that the probability of the solvent (in this case the API) 
making contact with the segment of polymer (in this case monomer) is equal to the 
volume fraction of the polymer segments, i.e. the corresponding monomer (Gong et al., 
1989). The Flory-Huggins interaction parameter χ is used to account for the enthalpy 
of mixing; the free energy of mixing of an API-polymer system ΔGm is given by 
Equation (2) 
 
 
∆𝐺𝑀
𝑅𝑇
= 𝑛𝑑𝑟𝑢𝑔 ln ∅𝑑𝑟𝑢𝑔 +  𝑛𝑝𝑜𝑙𝑦𝑚𝑒𝑟 ln ∅𝑝𝑜𝑙𝑦𝑚𝑒𝑟 +  𝑛𝑑𝑟𝑢𝑔 ∅𝑝𝑜𝑙𝑦𝑚𝑒𝑟𝜒𝑑𝑟𝑢𝑔−𝑝𝑜𝑙𝑦𝑚𝑒𝑟    (2) 
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where 𝑛𝑑𝑟𝑢𝑔  is number of moles of the drug, 𝑛𝑝𝑜𝑙𝑦𝑚𝑒𝑟  is number of moles of polymer, 
∅𝑑𝑟𝑢𝑔 is volume fraction of the drug, ∅𝑝𝑜𝑙𝑦𝑚𝑒𝑟  is the volume fraction of the polymer, 
𝜒𝑑𝑟𝑢𝑔−𝑝𝑜𝑙𝑦𝑚𝑒𝑟is the interaction parameter between the drug and polymer. By knowing 
the interaction parameter, χ, one can estimate the mixing behaviour of an API to 
polymer system using the Flory-Huggins theory via estimation of the free energy of 
mixing which in turn indicates the driving energetics of the process.  However the 
approach requires the interaction parameter χ to be estimated.  Earlier reports indicated 
that the solubility parameter and melting point depression approaches maybe used to 
estimate the miscibility and interaction parameter of a blend, respectively (Marsac et 
al., 2009; Marsac et al., 2006; Tian et al., 2013; Zhao et al., 2011).  
2.2.3 Interaction parameter estimation using the melting point approach  
 To derive the drug-polymer interaction parameter using the melting point 
depression approach, the melting data was used in Equation (3)  (Marsac et al., 2006; 
Paudel and Van den Mooter, 2011; Zhao et al., 2011). 
 
(
1
TMmix
-
1
TMpure
) =  
-R
∆Hfus
[ln ∅drug + (1-
1
m
) ∅polymer + χ12∅polymer
2 ]                    (3) 
where TMpure is the melting temperature of the pure API, TMmix is the depressed melting 
temperature of the mixture, R is the universal gas constant, ΔHfus is heat of fusion of 
the pure API, m is the volume ratio of polymer to its volume lattice (which is taken as 
the volume of drug),  χ12 is interaction parameter, ∅𝑑𝑟𝑢𝑔 and ∅𝑝𝑜𝑙𝑦𝑚𝑒𝑟 is the volume 
fraction of the drug and polymer respectively which were obtained from Equation (4).  
 
∅𝑑𝑟𝑢𝑔 =  
𝑉𝑑𝑟𝑢𝑔
𝑉𝑑𝑟𝑢𝑔+𝑉𝑝𝑜𝑙𝑦𝑚𝑒𝑟
               (4) 
 
where V is volume of the component which is denoted by its subscription. The volume 
of a component is calculated from the value of weight divided by value of density, i.e. 
V= m/ρ. 
 By rearranging Equation (3) and Equation (5), the interaction parameter, χ12 
between the drug-polymer could be obtained by plotting the function of depressed 
melting temperature of PCM against the volume fraction of the polymer, i.e.  
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[(𝑇𝑀𝑚𝑖𝑥
−1 ) − (𝑇𝑀𝑝𝑢𝑟𝑒
−1 ) ×
∆𝐻𝑓𝑢𝑠
−𝑅
] − [1 − (
1
𝑚
) × ∅𝑝𝑜𝑙𝑦𝑚𝑒𝑟] − [ln ∅𝑑𝑟𝑢𝑔] = χ12 × ∅polymer
2     (5) 
 
where volume fraction of the polymer were obtained by dividing the weight of the 
polymers used by their corresponding density which was obtained from product 
information from the supplier (ISP Pharmaceuticals, 2007). 
 
2.3 Practical preparation and characterization methods  
2.3.1 Preparation of physical mixtures 
 Physical mixtures of the APIs (i.e. PCM and CAF) and PVP carriers were 
weighed according to the desired drug-polymer ratio and the mixtures were gently 
mixed in a mortar and pestle for approximately 2 minutes. 
 
2.3.2 Melting point depression measurements 
To predict the interaction parameter using the melting point depression method, 
physical mixes were prepared in drug-rich proportions (from 75 - 95% w/w drug 
loading) and scanned by modulated DSC (Q2000, TA Instrument, Newcastle USA) 
with ± 0.212 oC every 40s at 2 oC per minute to 200 oC using aluminum pans. Pin-holed 
lids were used to allow removal of water, particularly given the hygroscopic nature of 
the PVP polymers (Callahan et al., 1982). Modulated mode was used to distinguish the 
Tg and relaxation endotherm of the polymer, particularly PVP K29-32, from the melting 
endotherm of PCM. All experiments were run in triplicate. 
  
2.3.3. Preparation of hot melt extruded solid dispersions 
To compare theoretical and practical approaches to assess miscibility, HME 
samples were prepared using Thermo Scientific HAAKE MiniLab II Micro 
Compounder with intermeshing twin screw extruder. PCM-loaded samples ranging 
from 20%-70% PCM were prepared for PVP, while 20%-50% PCM were prepared for 
PVPVA. For both HME system of CAF, 10% -20% and 10%-30% CAF systems were 
prepared, respectively. The temperature of extrusion was determined by the minimum 
temperature at which extrusion was possible over a reasonable drug concentration 
range. The difference between the API loadings is a reflection of experimental 
observations whereby the maximum loading was determined by the point at which the 
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appearance of the extrudate became opaque. The conditions chosen (temperature and 
loading) therefore represent the least aggressive that would produce clear extrudates, 
with the other manufacturing parameters being kept constant. Table 1 displays the 
processing parameters used in the production of the HME systems.  Note that extrusion 
of the PVP, PVPVA alone and caffeine-loaded extrudates at 120oC was not possible 
due to the high torque involved.    
 
Table 1:Parameters used in the production of HME systems 
Formulations (HME % w/w API-
carrier) 
Extrusion 
temperature (oC) 
Screw speed (rpm) 
Residence time 
(minutes) 
20-70% PCM PVP K29-32 120 100 5 
20-50% PCM PVPVA  120 100 5 
10-20% CAF PVP K29-32 155 100 5 
10-30% CAF PVPVA 180 100 5 
 
 
2.3.4 Attenuated total reflectance Fourier transform infrared spectroscopy 
 In order to confirm the existence of interactions between the API and carriers, 
attenuated total reflectance Fourier transform infrared spectroscopy (ATR-FTIR) 
measurements were carried on raw material, physical mixes and freshly ground 
extrudates. The spectra were recorded over a wavenumber range of 500 cm-1 to 4000 
cm-1 with a resolution of 2 cm-1 and 64 scans  using IFS-60/S Fourier transform infrared 
(Bruker Optics, Coventry, UK) with an ATR accessory.  
2.3.5 Powder X-ray diffraction 
 X-ray powder diffraction (XRPD) scans of raw materials, physical mixes and 
ground HME extrudates were performed using a Thermo ARL Xtra model 
(Switzerland) equipped with a copper X-ray Tube (1.540562 Å). The extrudates were 
crushed into powder form and compacted into the sample holder of the XRPD. 
Measurements were performed from 10o to 30o (2θ) coupled with scanning speed of 
0.01o / step and 1 second for every scan step to cover the characteristic peaks of the 
crystalline PCM and CAF.  
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2.3.6 Thermal analysis of HME systems 
 All the HME extrudates were cut into approximately 3-5mm strand and scanned 
by modulated DSC (Q2000, TA Instrument, Newcastle USA) with ± 0.212 oC every 
40s at 2 oC per minute to 250 oC using aluminum pans. Pin-holed lids were used to 
allow removal of water. Thermal events were further analyzed using hot stage 
microscopy (HSM) with polarized light to identify crystalline material via 
birefringence. A FP82HT hot stage equipped with a FP90 central processor (Mettler 
Toledo, Leicester, UK) was installed on a polarized microscope model (Leica, Milton 
Keynes, UK) with the JVC camera. Sample was heated at 10 oC per minutes from room 
temperature to 250oC. 
 
3. Results 
 
3.1 Solubility parameter calculations 
 
 The solubility parameters obtained from the Hoftzyer/Van Krevelen and Hoy 
methods have been previously suggested to provide good correlation with 
experimentally derived values obtained from heat of vaporization data (Van Krevelen 
and Te Nijenhuis, 2009). Therefore, in this study, solubility parameters used were the 
average values obtained from the two methods. Table 2 displays the calculated value 
for each method and their average as well as the difference between the solubility 
parameters of drug and polymer carriers.  
 
 
Table 2: Solubility parameters of the APIs and PVP polymers 
Compound Solubility parameter, δ             Δδ (δd - δp) 
 
Hoftyzer/ Van 
Krevelen (MPa)1/2 
Hoy 
(MPa)1/2 
Average 
(MPa)1/2 
PVP K29-32 
(MPa)1/2 
PVPVA 
(MPa)1/2 
Paracetamol 27.17 26.83 27.00 3.83 4.68 
Caffeine 35.19 27.48 31.34 8.17 9.02 
PVP K29-32 26.29 20.05 23.17   
PVPVA 24.38 20.54 22.32   
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 The difference in the solubility parameters between the drug and polymer is an 
indication of drug-polymer miscibility. When the difference is more than 10 MPa1/2, 
there is potential for immiscibility between the mixture components. Conversely, when 
the difference is less than 7 MPa1/2, the mixture is expected to a show good miscibility 
(Sarode et al., 2013; Thakral and Thakral, 2013; Zhao et al., 2011). The last two 
columns of Table 2 represent the differences of solubility parameters between the drug 
and polymer carriers. Binary systems of PCM-PVP and PCM-PVPVA are expected to 
show good miscibility, as indicated by the low differences between the PCM and its 
carrier systems (PVP and PVPVA; < 7 MPa1/2). On the other hand, the difference of 
the solubility parameters between the drug and polymer in binary systems of CAF-PVP 
and CAF-PVPVA is Δδ > 8 MPa1/2 suggesting a more limited miscibility of the drug 
and carriers.  These results therefore indicate that a greater miscibility is predicted for 
PCM in either carrier than is predicted for caffeine.  However, it is noteworthy that 
some miscibility is nevertheless predicted for the caffeine-polymer systems.    
 
3.2 Calculation of the interaction and related parameters via melting point 
depression  
 Drug-polymer miscibility was also estimated using the melting point depression 
approach. Fig. 1 shows an example of DSC traces of the depressed melting point of 
PCM in the PM of binary PCM-PVP ranging from 75% to 100% of drug loading.   An 
apparent melting point depression was detected for PCM in the presence of PVP in 
which the onset of Tm of PCM was recorded as 156
oC at 75% w/w PCM. The melting 
point depression for caffeine was considerably less marked (raw data not shown).    
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Figure 1. DSC traces of physical mixes of PCM-PVP from (a) 75%, (b) 80% , (c) 85%, (d) 
90%, (e) 95%, and (f)100 % w/w drug loading) measured at 2 oC/min. Onset melting points 
of each the DSC thermogram were taken as the melting temperature of the corresponding 
systems. 
 Melting point depression of the drug system is attributed to the change in overall 
chemical potential of the mixture as a result of interactions between the drug and the 
polymer (Tian et al., 2013; Zhao et al., 2011). These interactions include Van der 
Waals, hydrogen bond, charge transfer as well as (potentially) ionic interactions. 
Structurally, hydrogen bond formation was anticipated between PCM and PVP due to 
the presence of a proton donor in PCM and proton acceptor in the pyrrolidone moiety 
of PVP. However, this is not anticipated in the binary CAF and PVP because of the 
lack of a proton donor in the CAF molecule. Therefore, the difference in ability of 
hydrogen bond formation between the PCM-PVP and CAF-PVP systems may explain 
the different degree of melting point depression. In the context of HME, the depressed 
melting temperature will promote flowability of the mixture in the HME; this may 
potentially allow a favorable mixing process between the drug and polymer at 
temperatures lower than anticipated from the melting data of the pure drug, as indeed 
was found for PCM (see Table 1).  
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 Fig. 2 displays a function of the depressed melting temperature against volume 
fraction of PVP polymers (based on Equation 5), with the slopes yielding the interaction 
parameter, χ12. 
 
 
Figure 2. Plot used to determine the interaction parameters of PCM-PVP, PCM-PVPVA, 
CAF-PVP and   CAF-PVPVA systems. 
   
 
 Note that the caffeine systems yielded R2 values < 0.9 hence it was considered 
inappropriate to calculate the interaction factor from this data.  According to the 
relationship between the free energy of mixing and the interaction parameter as 
presented in Equation (2), a favorable mixing can be realized only if the drug-polymer 
interaction parameter is negative. In addition, the smaller the magnitude of the 
interaction parameter would give rise to a more negative free energy mixing, ΔGm, thus 
a more negative interaction parameter indicates a higher potential for drug-polymer 
interaction. Table 3 summarizes the interaction parameters of the PCM-polymer 
systems, whereby in both cases the interaction parameters are negative. The interaction 
parameter of PCM-PVP is more negative than PCM-PVPVA at a temperature close to 
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the melting of the APIs which implies a better interaction between PCM and PVP than 
between PCM and PVPVA. 
Table 3: Flory-Huggins interaction parameters based on melting point depression of 
physical mixtures of paracetamol with PVP/PVPVA 
Formulation Interaction parameters, χ12 Correlation, R2 
PCM / PVP  -1.2525 0.9498 
PCM / PVPVA  -0.7947 0.9412 
 
 To extend the analysis, the free energy of mixing (ΔGm) of the PCM systems were 
also calculated based on the interaction parameters from Table 3 by using Equation (1) 
in section 2.2. Fig. 3 displays the obtained Gibbs free energy values plotted against the 
volume fraction of PVP carriers. 
 
Figure 3. The changes in free energy of mixing of the API and polymer systems as a 
function of volume fraction of polymer as predicted using interaction parameter of Flory-
Huggins  lattice theory :   ̶ ̶  ▪  ̶ ̶̶ ̶  PCM/PVP, and - - - - PCM/PVPVA.  
 
 The Gibbs free energies for the PCM mixtures were negative which indicated 
miscibility of the PCM and the carriers. This is in good agreement with the conclusions 
drawn from the (close) values of the solubility parameters (Table 2).  According to Fig. 
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3, the minimum negative value of the PCM-PVPVA system lies at a higher value of 
polymer fraction (i.e. at 0.7 mole fraction of PVPVA) compared to PCM-PVP which 
has a minimum at 0.6 mole fraction of polymer. This indicates that a higher PVPVA 
fraction is needed to achieve a maximum miscibility between PVPVA and PCM in 
comparison to the homopolymer. These predictions will be correlated to the physical 
structure of the SD extrudates in a later section.   
 The lower extent of melting point depression seen for the CAF systems and the 
poor fit to Equation 5 rendered similar treatment of the data for this drug inappropriate.  
It should be noted that overall, the analysis indicated a much more favorable interaction 
parameter for the PCM systems with both polymers than did the CAF study, reinforcing 
the proposal that the former drug exhibits a much stronger level of molecular interaction 
than does CAF.     
 
3.3 HME processability of the API-polymer systems 
 
 It has been suggested that HME products need to be processed at an extrusion 
temperature  (Tex) approximately 30-60
oC higher than glass transition temperature (Tg) 
of the polymer to allow the polymer to have a viscosity low enough to allow extrusion 
(Chokshi et al., 2005; Li et al., 2014; McGinity et al., 2006).  However, it is also 
necessary to consider the liquefaction of the drug within the processing apparatus, as 
the presence of a suspension would be expected to increase viscosity and hence impede 
processing. On that basis, it is generally accepted that the Tex must be high enough to 
both reduce polymer viscosity and facilitate liquefaction of the drug, either via melting 
or dissolution or both in preparing amorphous solid dispersion. While no issues for 
extrusion were envisaged for PVPVA due to its low Tg (at circa 106
oC), initial attempts 
at processing PVP alone at any temperature lower than 180oC (higher than the Tg of 
PVP =164oC) failed to result in extruded product because the torque was too high to 
allow extrusion. There is therefore clearly a challenge in identifying conditions that 
allow polymer processing in order to avoid degradation whilst also allowing the drug 
to dissolve or melt. Previous studies have suggested that extrusion may take place at 
Tex < Tm of the drug (Li et al., 2014; Shah et al., 2013) due to plasticization and/or 
interaction effects, while Guo et al. (2013) have suggested that thermosensitive drugs 
may be successfully extruded at temperatures around the glass transition of the 
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polymer.  However, to date there has been limited evidence that the presence of the 
drug may in fact allow extrusion at a temperature much lower than the Tg of the 
polymer, with concomitant positive implications for thermal stability.  Furthermore, the 
respective roles of direct molecular interaction and simple miscibility in allowing such 
a decrease in processing temperature is not yet clear.   
 In this study, the extrusion temperatures were initially explored on the basis of 
the extrudability of the binary products. For both drugs, temperatures which were 
approximately 50oC lowered in comparison to the Tm of the drug were found to be 
effective. A Tex value of 120
oC was chosen for HME PCM systems; this is of interest 
as it is lower than the Tg of the polymer alone, indicating extensive plasticization of the 
system by the PCM and thereby allowing lower temperature extrusion than would be 
usually expected. A Tex of 180
oC was initially chosen for HME CAF systems and found 
to be suitable for extrudability despite being well below the Tm of caffeine.  However, 
subsequent testing of PVP using thermogravimetric analysis showed that there was 
potential degradation of PVP at 180oC, hence for HME CAF PVP products the lower 
temperature of 155oC was selected; it is interesting to note that the caffeine was also 
effective in reducing the temperature of extrudability of the PVP (which could not be 
successfully extruded alone at 180oC) despite there being no evidence for interaction 
and limited predicted mesicibility. It was therefore not possible to use exactly the same 
conditions for all four systems; instead, in all four cases the minimum temperatures that 
could be safely used were selected (Table 1). In terms of maximum loading, this 
parameter was determined by the visual appearance of the extrudates. More 
specifically, the maximum concentration was determined by the appearance of opacity 
in the extrudates. Examination of Table 1 shows that not only was it possible to use 
lower processing temperature from PCM compared to CAF, but that the former could 
also be incorporated up to higher concentrations before the extrudates appeared opaque.  
Clearly, therefore, the two drugs exhibit very different processability profiles in terms 
of both temperature and loading. This in turn indicates that the differing miscibility 
between the two, which we ascribe at least partially to direct molecular interactions, 
may have a profound effect on the choice of processing parameters.  However, the use 
of the interactive and non-interactive drugs allows illustration of the point that while 
the interactive system allowed a greater lowering of processing temperature, the non-
interactive drug-polymer system also showed a considerable reduction in Tex which we 
tentatively ascribe to simple dissolution of the drug in the polymer.     
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3.4 Interaction assessment using ATR-FTIR 
 
  Fig. 4 shows the ATR-FTIR spectra of pure PCM, PVP, the PM and HME of 20-
70% PCM PVP. The carbonyl (C=O) group stretching of the PVP monomer is seen at 
1652 cm-1; after HME processing of PVP with PCM, this band was shifted to a lower 
frequency of 1647 cm-1, indicating interaction with the API at this carbonyl group. The 
ATR-FTIR spectrum of crystalline PCM indicates a characteristic band at 3324 cm-1 
which is attributed to NH stretching; this band was broadened in the HME product.  
Furthermore, the –OH stretching band of crystalline PCM at 3100 cm -1 was also 
broadened in the HME PCM PVP products. Both changes of these characteristic peaks 
indicated different vibration modes of -NH and –OH in the HME PVP-based SD 
compared to the pure drug.  
 
 
Figure 4. ATR-FTIR spectra of PCM, PVP and HME PCM-PVP systems 
  Combining the observations of the down-shifted carbonyl stretching band in PVP 
monomer and the broadening in –NH/-OH stretching band of PCM molecules, it is 
suggested that hydrogen bond interactions are formed between the C=O group of the 
PVP monomer and the NH or OH groups of PCM; this is in agreement with previously 
reported literature (Illangakoon et al., 2014; Nair et al., 2001; Wang et al., 2002). In the 
fingerprint region of circa 900-700 cm-1, triplet peaks were seen for pure PCM and PM 
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50% PCM-PVP. However, in HME products, only a doublet was seen. According to 
Qi et al., the triplet peaks in this region may be attributed to crystalline PCM, whereas 
a doublet peak infers amorphous PCM (Qi et al., 2008). Therefore, based on the ATR 
FTIR spectra in Figure 4, HME 10% to 50% PCM PVP extrudates were amorphous in 
nature as shown by the double band in print region of 900-700 cm-1. At higher PCM 
loading of HME PVP-based (60% and 70%) SD, the ATR-FTIR spectra show the 
reappearance of the diagnostic peaks of crystalline PCM (3100, 3324 and 807 cm-1) 
which suggests the presence of crystalline material in those samples.  
  Fig. 5 shows the ATR-FTIR spectra of pure PCM, PVPVA and HME PCM-
PVPVA systems. The ATR-FTIR spectra of PVPVA indicates two peaks at C=O 
stretching region, i.e. 1734 cm-1 and 1667 cm-1 which correspond to the C=O stretching 
of vinyl acetate and pyrrolidone, respectively. 
 
 
Figure 5. ATR-FTIR spectra of PCM, PVPVA and HME PCM-PVPVA systems 
 Interestingly, it is found that the C=O stretching (1734 cm-1) of the VA moiety in 
both PM and HME preparations of binary PCM-PVPVA did not shift in comparison to 
the spectra of PVPVA alone. This is in contrast to the C=O stretching of pyrrolidone 
where down-shifting of its peak position (from 1667 cm-1 to 1653 cm-1) was noted in 
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HME PCM-PVPVA in comparison to the PM and raw PVPVA. Therefore it is believed 
that the main interactions between PCM and PVPVA occurs preferentially at the C=O 
group of the pyrrole group rather than the C=O in vinyl-acetate group. On that basis, 
the intensity of PCM-polymer interaction was higher in PVP carrier system than in the 
HME PVPVA system.  
Fig. 6 compares the ATR-FTIR spectra of CAF, PVP and HME CAF in PVP. 
ATR-FTIR spectra of HME 10-20% CAF in PVP did not show any significant peak 
position shifts in the carbonyl stretching region of the PVP as compared to its 
corresponding PM. This was attributed to the absence of molecular interactions 
between the CAF and PVP molecules. Similar results were found for PVPVA systems 
(data not shown).  
 
 
Figure 6. ATR-FTIR spectra of CAF, PVP and HME CAF-PVP systems 
 
 To summarise the ATR-FTIR results, PCM has been shown to demonstrate 
evidence for an interaction between the drug and the carriers PVP and PVPVA, with 
evidence for involvement of the C=O group of the PVP monomer and the NH and/or 
OH groups of PCM. The interaction between PCM and PVPVA was weaker and 
occurred preferentially at the C=O group of the pyrrole group. However, CAF has 
shown no evidence for interaction within the extrudated systems.  Evidence was also 
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obtained for phase separation into crystalline drug phases for PCM at 50% w/w loading 
in HME PVPVA system.  
 
3.5 X-ray Powder Diffraction of HME solid dispersions 
 
3.5.1 HME PCM-PVP and PVPVA systems 
Fig. 7 shows the XRPD diffractograms of the extruded PCM PVP systems. The 
diffractograms showed halo patterns up to 50% drug loadings. At higher PCM loading 
i.e. 60%-70%, diffraction peaks were noted as anticipated from the opaque appearance 
of the extrudate at these loadings, indicating the presence of crystalline material in 60%-
70% PCM loading system.  
 
Figure 7. X-ray Diffraction patterns of PCM and PVP, a) HME 20% PCM, b) HME 30% 
PCM , c) HME 40% PCM, d) HME 50% PCM, e) HME 60% PCM, f) HME 70% PCM, g) 
PM 20% PCM  and h) Pure PCM 
 The peaks in the X-ray diffractograms of HME 60% and 70% PCM PVP 
corresponded to the initial polymorphic form, i.e. Form I (Łuczak et al., 2013). The 
detection of  crystalline material for HME 60% PCM-PVP and above was a reflection 
of the relatively low extrusion temperature, i.e. 120oC, which allowed limited 
dissolution  up to 50% drug loading in PVP. However, a reduction in crystalline content 
Degree (2Ɵ) 
In
te
n
si
ty
 
23 
 
were still seen in extrudates with 60% and 70% drug loading, which were found to have 
13.72% and 29.25 % of crystallinity respectively. The percentage of crystalline material 
within the extrudates was calculated based on calibration according to the intensity of 
the two sharp peaks at 23.4 and 24.5o 2θ from XRPD diffractograms of physical 
mixtures of PCM and polymer with known crystalline percentage (de Villiers et al., 
1998). 
 Fig. 8 shows the XRPD data of HME PCM in PVPVA systems. Unlike PVP 
carriers systems, the HME 50% PCM-PVP gave rise to X-ray diffraction peaks with a 
calculated crystallinity of 10.52%. This in turn implies that the solubility limit of PCM 
in PVPVA is lower than that in PVP using the same extrusion temperature of 120oC.  
  
Figure 8. X-ray diffraction patterns of PCM with PVPVA a) HME 20% PCM, b) HME 
30% PCM, c) HME 40% PCM, d) HME 50% PCM, e) PM of 20 % PCM-PVPVA 
 
 
3.5.2 HME CAF-PVP and PVPVA systems 
 XRPD was also used to analyze extrudates of HME CAF in PVP systems. Fig. 9 
displays the XRPD spectra of CAF, PM and HME of CAF PVP. A halo pattern was 
only detected in HME 10% CAF-PVP. In XRPD diffractograms of HME 20% CAF-
PVP, a single characteristic peak at 2θ = 26.86o was noted which is attributed to 
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metastable Form I CAF (Fig.9d, arrowed) (Descamps and Decroix, 2014). The 
detection of Form I in the hot processed HME PVP-based extrudates may reflect the 
enantiotropic nature of this material, with Form I being generated at higher 
temperatures (Descamps et al., 2005; Descamps and Decroix, 2014; Kishi and 
Matsuoka, 2010), although clearly the form has persisted on cooling. Since the peaks 
in the X-ray diffractograms of HME PVP-based CAF systems indicated a different 
polymorphic form of CAF which was different from the PM of raw CAF, the 
percentage of CAF crystallinity in the HME extrudates was not calculated.  
 
Figure 9. X-ray diffraction patterns of, a) HME  10% CAF PVPVA, b) HME 20% CAF 
PVPVA, c) HME 30% CAF PVPVA, d) HME 10% CAF PVP e) HME 20% CAF PVP, f) 
PM of 10% CAF PVPVA g) commercial CAF as received 
Compared to HME CAF-PVP, a higher non-crystalline loading was noted for 
HME CAF PVPVA as shown by its halo patterns in XRPD diffractograms at 20% drug 
content (Fig. 11b). This might be ascribed to the higher extrusion temperature employed 
in HME PVPVA system (i.e. 180 oC) as compared to PVP (i.e. 155 oC). Similarly to 
the HME 20% CAF-PVP, XRPD diffractograms of the extruded 30% CAF-PVPVA 
system indicated single peaks at 2θ = 26.86o which was attributed to the Form I CAF 
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(Fig. 9c); this is due to the transformation of CAF Form II (raw) to Form I during 
processing at 180oC.  Nevertheless, some limited miscibility (at 10% w/w drug loading) 
was noted for the CAF systems.   
 
3.6 Thermal analysis of the HME polymer systems 
The DSC data of PCM-PVP and PCM –PVPVA HME systems showed melting 
peaks at 60%PCM PVP and 50% PCM PVPVA system (data not shown), hence the 
data indicated that the drug was molecularly dispersed up to these concentrations, as 
found using XRPD.  The glass transition values were measured as lying between 31.3 
to 76.2oC for HME PCM PVP system and 37.2 to 46.6oC for PCM PVPVA systems, 
although the possibility of water plasticization on the cooled materials could not be 
excluded and hence these values were not considered further as a direct measure of 
drug-polymer miscibility.  
A more complex profile was noted for the CAF-loaded systems (Figure 10).  DSC 
traces showed an endothermic response for both 10% and 20% CAF PVP systems 
between 207oC to 233oC which is close to the melting temperature of crystalline CAF. 
However there was also evidence for recrystallisation during the heating run, hence the 
presence of the endotherm could not be taken as definitive evidence of the presence of 
crystalline material in the original sample.  Indeed, for 20% PVPVA systems there was 
a clear exotherm which we attribute to caffeine recrystallization during heating. This 
was further supported by HSM data whereby crystals were seen to appear at circa 112oC 
(Figure 11).     
26 
 
 
Figure 10. MTDSC thermograms of (a) HME 10% CAF-PVP, (b) HME 20% CAF, (c) 
HME 10% CAF-PVPVA and (d) HME 20% CAF-PVPVA 
 
 
Figure 11. HSM investigation of HME 10% CAF-PVPVA at a heating rate of 10 oC per 
minute. The marked temperature at left bottom corner of each screen indicates the 
temperature of sample. Polarized light was used in screen (b) and (c) 
 
Overall, therefore, the thermal analysis studies have broadly supported the 
conclusions from the FTIR and XRD in suggesting that a molecular dispersion is 
generated for PCM at concentrations up to circa 60% w/w, while for caffeine the 
miscibility is much lower, despite the higher extrusion temperatures used.   
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4. Discussion 
 
 The study has explored the miscibility, processability and final structure of HME 
systems prepared using two model drugs with very different propensities for interaction 
with the two polymers used.  In considering the findings, it is necessary to delineate the 
phenomena involved as while interrelated they are nonetheless distinct.  The intrinsic 
miscibility between the drugs and polymers will be dependent on several factors, one 
being the possibility of direct molecular interaction, another being the similarities in 
hydrophobicity and hydrophilicity of the two component structures. By using two drugs 
with different propensities for interaction, it is possible to examine how such 
interactions may influence both miscibility and processability, the latter being 
considered in terms of both temperature at which processing is possible and the 
maximum drug loading that may be used to produce clear (and potentially molecularly 
dispersed) products.    
 The extent of miscibility was assessed using theoretical approaches in the first 
instance. It is reported that when differences in Hansen’s solubility parameters of drug-
polymer mixes are < 7.0 MPa1/2, significant miscibility between the two components is 
expected (Maniruzzaman et al., 2013; Sarode et al., 2013; Thakral and Thakral, 2013; 
Zhao et al., 2011). In this study, good miscibility was predicted in the binary system of 
the interacting API (PCM) and the PVP-based polymers, as shown by the small 
difference in their solubility parameters. In contrast, solubility parameters of the non-
interacting API, i.e. CAF with PVPs polymers show differences of > 8 MPa1/2 which 
imply limited miscibility. From the melting point depression approach, similar 
conclusions may be drawn in that there was a clear indication of greater miscibility for 
the PCM systems.   
 In terms of experimental assessment of the HME systems, the ATR-FTIR again 
supports a greater interaction between the PCM and the two polymers than was the case 
for CAF, hence it is reasonable to conclude that the two model drugs show clear 
predicted miscibility differences which may reasonably be associated with the presence 
or absence of molecular interactions between the drug and polymer.  
Examination of both the conditions used to produce HME dispersions indicated 
that lower temperatures could be used for PCM systems, to the extent that it was 
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possible to process at temperatures below Tg of the pure polymers. This would strongly 
indicate plasticizing effects which in turn indicates miscibility of the PCM with the 
polymers used. However similar lowering, at least in relation to the melting point of 
the drug, was seen for caffeine, indicating that the drug was also acting as a plasticizer 
despite the lack of direct interaction with the polymer. Nevertheless, the drug loading 
which could be effectively processed into an amorphous dispersion system was much 
lower than for PCM.  The phase separation in the cooled extrudates were also examined 
using FTIR, XRD and DSC, with good agreement between data sets in that the PCM 
systems were molecularly dispersed up to circa 50% w/w as opposed to circa 20% for 
CAF.  
Overall, therefore, the study has shown that a high level of molecular interaction 
does appear to increase the maximum concentration that may be incorporated at a 
molecular level and may also facilitate lowering of Tex. Consequently, such interactions 
may be beneficial in terms of maximum loading and for facilitating processability.  The 
study has also highlighted the role of such interactions in facilitating the use of PVP in 
particular as a matrix for extrusion.  However the study has also shown that such 
interactions, at least at a level detectable by spectroscopic techniques, are not in fact 
essential for successful reduction in processing temperature and molecular dispersion 
formation, as evidenced by the successful lowering of the Tex and the molecular loading 
of the CAF systems.  One may therefore conclude that direct interaction is therefore 
extremely helpful, but is not essential in forming suitable HME formulations.     Indeed, 
examination of the predictive tools used would indicate that solubility parameters, 
which incorporate molecular interactions but are not dominated by them, may be an 
effective means of predicting not only miscibility but also processing suitability of 
drug-polymer combinations. 
     
5. Conclusions 
 
 This study has examined the miscibility of two model APIs, caffeine (CAF) and 
paracetamol (PCM), in PVP-based solid dispersions prepared via hot melt extrusion.  It 
has been shown that the solubility parameter and melting point depression methods may 
be used to assess comparative miscibility at an early stage, with good correlation found 
between such approaches and subsequent processing behavior and structure. PCM was 
predicted to be more miscible in both polymers (especially PVP homopolymer), this 
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being supported by practical evidence with regard to phase separation on extrusion. The 
miscibility of PCM was attributed to hydrogen bonding which was absent for CAF, an 
assertion supported by ATR-FTIR. In terms of processing, the interactive systems 
(PCM-based) could be processed at temperature below the Tg of the polymer alone 
which can be reasonably ascribed to plasticization effects.  Similarly, the maximum 
loading which produced clear extrudates was also higher for the PCM systems. 
However, the non-interacting CAF systems also showed extrusion temperature 
lowering and molecular miscibility, albeit to a lesser extent.     
 Overall, the study has shown that miscibility and molecular interactions may be 
intrinsically linked and indeed predicted from theoretical approaches, with implications 
for both extrudability and phase separation.  However direct interactions do not appear 
to be essential for either improvements in processability and molecular dispersion, 
hence examination of solubility parameter difference may in itself be an effective 
means of determining suitability of drug-polymer combinations for enhanced 
performance, irrespective of interaction potential.    
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List of Figure  
 
Figure 1. DSC traces of physical mixes of PCM-PVP from (a) 75%, (b) 80% , (c) 85%, 
(d) 90%, (e) 95%, and (f)100 % w/w drug loading) measured at 2 oC/min. Onset melting 
points of each the DSC thermogram were taken as the melting temperature of the 
corresponding systems. 
Figure 2. Plot used to determine the interaction parameters of  
PCM/PVP,PCM/PVPVA, CAF-PVP and   CAF-PVPVA systems. 
Figure 3. The changes in free energy of mixing of the API and polymer systems as a 
function of volume fraction of polymer as predicted using interaction parameter of 
Flory-Huggins  lattice theory :   ̶ ̶  ▪  ̶ ̶̶ ̶  PCM/PVP, and - - - - PCM/PVPVA. 
Figure 4. ATR-FTIR spectra of PCM, PVP and HME PCM-PVPVA systems 
Figure 5. ATR-FTIR spectra of PCM, PVPVA and HME PCM-PVPVA systems 
Figure 6. ATR-FTIR spectra of CAF, PVP and HME CAF-PVP systems 
Figure 7. X-ray Diffraction patterns of PCM and PVP, a) HME 20% PCM, b) HME 
30% PCM , c) HME 40% PCM, d) HME 50% PCM, e) HME 60% PCM, f) HME 70% 
PCM, g) PM 20% PCM  and h) Pure PCM 
Figure 8. X-ray diffraction patterns of PCM with PVPVA a) HME 20% PCM, b) HME 
30% PCM, c) HME 40% PCM, d) HME 50% PCM, e) PM of 20 % PCM-PVPVA 
Figure 9. X-ray diffraction patterns of, a) HME  10% CAF PVPVA, b) HME 20% CAF 
PVPVA, c) HME 30% CAF PVPVA, d) HME 10% CAF PVP e) HME 20% CAF PVP, 
f) PM of 10% CAF PVPVA g) commercial CAF as received 
Figure 10. MTDSC thermograms of (a) HME 10% CAF-PVP, (b) HME 20% CAF, (c) 
HME 10% CAF-PVPVA and (d) HME 20% CAF-PVPVA 
Figure 11. HSM investigation of HME 10% CAF-PVPVA 6:4 at a heating rate of 10 
oC per inute. The marked temperature at left bottom corner of each screen indicates the 
temperature of sample. Polarized light was used in screen (b) and (c) 
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Supplementary information 1 
Water content (% w/w) of freshly prepared HME extrudates as a function of drug-polymer composition 
Drug loading 
% w/w 
Water content (%w/w) 
HME PCM- PVP K29-32 HME PCM-PVPVA HME CAF-PVP K29-32 HME CAF-PVPVA 
10 - - 2.68 ± 0.52 2.33 ± 0.42 
20 1.86 ± 0.29 2.49 ± 0.37 2.56 ± 0.10 2.11 ± 0.36 
30 1.59 ± 0.39 1.66 ± 0.12 - - 
40 1.84 ± 0.57 1.64 ± 0.17 - - 
50 2.02 ± 0.75 1.28 ± 0.17 -  
60 1.92 ± 0.47 - - - 
70 1.59 ± 0.16 - - - 
 
Supplementary information 2 
Tg of the HME extrudates as a function of drug-polymer composition 
 
Drug 
loading 
% w/w 
Glass Transition temperature (oC) 
HME PCM- PVP K29-32 HME PCM-PVPVA HME CAF-PVP K29-32 HME CAF-PVPVA 
10 - - 106.3 ± 9.2 59.0 ± 1.0 
20 76.2 ± 0.5 46.6 ± 2.9 82.1 ±1.8 51.6 ± 3.2 
30 60.6 ± 1.6 44.1 ± 2.0 - - 
40 54.8 ± 1.0 41.3 ± 0.5 - - 
50 42.5 ± 1.9 37.2 ± 0.7 -  
60 33.6 ± 2.4 - - - 
70 31.3 ± 0.7 - - - 
 
 
Supplementary information 3 
Raw data of depressed melting temperatures of PM system 
Solid dispersion systems 
Drug loading  
(% w/w) 
Onset melting point (oC) Melting enthalpy (KJ/mol) 
PCM-PVP K29-32 70 149.92 ± 471 13.72 ± 0.36  
 75 159.28 ± 2.51 15.36 ± 0.13 
 80 162.82 ± 2.37 17.45 ± 0.57 
 85 163.53 ± 0.44 18.83 ± 0.23 
 90 165.36 ± 0.36 20.66 ± 0.13 
 95 166.47 ± 0.21 23.23 ± 0.41 
 100 167.45 ± 0.26 27.83 ± 0.49 
    
PCM-PVPVA 70 145.40 ± 4.98 12.47 ± 0.15 
 75 156.29 ± 5.67 14.40 ± 0.73 
 80 159.68 ± 1.21 15.90 ± 0.32 
 85 161.62 ± 1.59 17.52 ± 0.64 
 90 165.09 ± 0.43 20.60 ± 0.57 
 95 166.30 ± 0.21 23.36 ± 0.91 
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 100 167.45 ± 0.26 27.83 ±0.49 
    
CAF-PVP K29-32 70 223.07 ± 0.88 9.94 ± 0.16 
 75 226.72 ± 0.27 12.40 ± 064 
 80 227.18 ± 2.83 13.09 ± 1.19 
 85 230.27 ± 1.23 14.49 ± 1.38 
 90 232.30 ± 0.95 18.08 ± 0.55 
 95 233.05 ± 106 18.06 ± 1.03 
 100 233.78 ± 0.14 24.27 ± 0.36 
    
CAF-PVPVA 70 220.21 ± 1.19 10.17 ± 0.98 
 75 224.87 ± 1.37 11.87 ± 0.83 
 80 228.54 ± 0.60 14.11 ± 0.38 
 85 229.47 ± 1.62 15.73 ± 0.32 
 90 230.36 ± 1.86 16.53 ± 0.65 
 95 231.52 ± 1.57 18.01 ± 0.56 
 100 233.78 ± 0.14 24.27 ± 0.36 
 
